Response of low-grade oligodendroglial tumors to temozolomide.
Byrne
Thomas N
TN
Neurosurgery and Internal Medicine, Yale University School of Medicine, USA.
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D018849:Controlled Clinical Trials as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D019656:Loss of Heterozygosity; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000235:genetics; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide